Mylan issues US recall of some EpiPen and EpiPen Jrs

Faith Castro
April 12, 2017

The initial recall of the emergency allergy product didn't include the U.S., but Mylan issued a new recall last night which not only includes EpiPens sold in the United States but also involves the children's version, known as EpiPen Jr.

The affected EpiPens were distributed from between December 17, 2015, to July 2016.

Both have expiry dates of May this year. After recalling over 80,000 EpiPens worldwide recently, the company announced it had received two separate reports of potentially faulty devices outside the U.S. Parents will naturally be wondering which Mylan EpiPens have been recalled, as this could be a serious health hazard to a child who relies on the lifesaving benefits of the EpiPen.

It says the defect is very rare and so far tests have not been able to replicate the failures, and the recalls are entirely cautionary.

Mylan is committed to replacing recalled devices at no cost and Mylan would like to reassure patients that there will be no additional replacement-related financial burden to them as a result of this recall.

The EpiPen 0.3 mg has an expiry date of May 2017 and lot number 5GU763. Furthermore, all patients should take comfort in knowing that the whole of this recall is being conducted with full and open supervision of the United States Food and Drug Administration.

More news: United Airlines CEO apologizes as stock valuation drops by $1 billion

EpiPen is made by a company called Mylan, which you may recognize from the recent controversy over its significant price hikes over the course of last few years.

The company said Friday the issue was extended to the USA and certain markets in Europe, Asia and North and South America.

The injection is used to counteract unsafe allergic reactions, such as those from bee stings or food allergies.

"We are asking patients to keep their existing product until their replacement product can be secured", the company said.

This voluntary recall is being conducted with the knowledge of FDA.

Other reports by LeisureTravelAid

Discuss This Article

MOST POPULAR LeisureTravelAid

FOLLOW OUR NEWSPAPER